Floxabactin vet 50 mg tabletti פינלנד - פינית - Fimea (Suomen lääkevirasto)

floxabactin vet 50 mg tabletti

le vet. b.v. - enrofloxacin - tabletti - 50 mg - enrofloksasiini

Floxabactin vet 150 mg tabletti פינלנד - פינית - Fimea (Suomen lääkevirasto)

floxabactin vet 150 mg tabletti

le vet. b.v. - enrofloxacin - tabletti - 150 mg - enrofloksasiini

Exparel liposomal האיחוד האירופי - פינית - EMA (European Medicines Agency)

exparel liposomal

pacira ireland limited - bupivacaine - acute pain - amides, anesthetics, local - exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.

Metronidazole Braun 5 mg/ml infuusioneste, liuos פינלנד - פינית - Fimea (Suomen lääkevirasto)

metronidazole braun 5 mg/ml infuusioneste, liuos

b. braun melsungen ag - metronidazole - infuusioneste, liuos - 5 mg/ml - metronidatsoli

NITIGRAF 300 mg I/ml injektioneste, liuos פינלנד - פינית - Fimea (Suomen lääkevirasto)

nitigraf 300 mg i/ml injektioneste, liuos

juste s.a.q.f - iohexolum - injektioneste, liuos - 300 mg i/ml - joheksoli

NITIGRAF 350 mg I/ml injektioneste, liuos פינלנד - פינית - Fimea (Suomen lääkevirasto)

nitigraf 350 mg i/ml injektioneste, liuos

juste s.a.q.f - iohexolum - injektioneste, liuos - 350 mg i/ml - joheksoli

Eucreas האיחוד האירופי - פינית - EMA (European Medicines Agency)

eucreas

novartis europharm limited - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.